Merck in Medical Technology

Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance

SAN DIEGO, Feb. 24 /PRNewswire/ -- Ambrx Inc, and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced a global strategic collaboration to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis. ARX424 was created by A...

Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The c...

Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.

Orchid Pharma partners with Diakron MORRIS PLAINS, N.J., Aug. 13 /PRNewswire/ -- Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I ...

MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.

MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ -- MicroDose Technologies Inc. (MicroDose) today announced that the first clinical milestone in its collaboration with Merck & Co., Inc., through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement f...

NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.

SOPHIA ANTIPOLIS, France, May 13 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new n...

Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch

- Merck to Conduct Preclinical Proof-of-Principle Studies - GAITHERSBURG, Md., April 3, 2008 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI ) today announced that it has signed an agreement with Merck & Co., Inc. to conduct proof-of-principle preclinical studies evaluating th...

Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.

SILVER SPRING, Md., March 11 /PRNewswire-USNewswire/ -- In a boost to HIV prevention research, Merck & Co., Inc., has agreed to provide a royalty-free license to the non-profit International Partnership for Microbicides (IPM) to develop a novel antiretroviral compound for use as a potential va...

Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation

Great Neck, N.Y., Jan. 18 /PRNewswire/ -- On January 17, 2008, the law firms of Parker Waichman Alonso LLP, Becnel Law Firm, LLC, Douglas & London P.C., Levin Simes Kaiser and Gornick LLP, Bailey Perrin Bailey LLP and Weitz & Luxenberg, P.C., have filed over a Billion ($1,000,000,000) Dollar C...

Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.

SAN DIEGO, Dec. 18 /PRNewswire/ -- Ambrx Inc. today announced that it has entered into a global, strategic collaboration with Merck & Co. Inc. to develop a novel therapeutic protein with biological properties similar to Fibroblast Growth Factor 21 (FGF-21) for the treatment of type 2 diabetes ...

MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders

NEW YORK, Dec. 13 /PRNewswire-USNewswire/ --- The Michael J. Fox Foundation for Parkinson's Research has committed up to $2 million for research toward therapies to alleviate Parkinson's-related cognitive dysfunction and mood disorders. The funding is to be awarded under a new initiative, Cogn...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...T201) also binds to EpCAM and is being developed under a collaboration with merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma...d the risks associated with reliance on collaborators, including MedImmune, merck Serono, TRACON and Nycomed, for the funding or conduct of further developme...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...T201) also binds to EpCAM and is being developed under a collaboration with merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma...d the risks associated with reliance on collaborators, including MedImmune, merck Serono, TRACON and Nycomed, for the funding or conduct of further developme...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

...ein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the comp...

Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech

...ch from a group of nine companies shortlisted for the award. Other awardees included GlaxoSmithKline Biologicals for Best Vaccine R&D Pipeline and merck for Best Prophylactic Vaccine. "This award caps a remarkable period of rapid progress and success in translating Sanaria's whole-organism, sporoz...

Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions

...ein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the comp...

Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS

...ships with a number of global pharmaceutical companies, including Novartis, merck & Co., Inc., Wyeth, and Sanofi Pasteur. The Company's pipeline inc...ted vaccine, a vaccine program for S. aureus, which is being developed with merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumoco...

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis

... SEATTLE and GENEVA, April 30 /PRNewswire/ -- merck Serono, a division of merck KGaA, announced today detailed results of the two-...he CLARITY study," said Elmar Schnee, President of merck Serono. "This is an exciting development in multip...

Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference

...ylvania Medical School, co-developed the rotavirus vaccine manufactured by merck & Co., Inc. He has also been a strong defender of vaccines. Dr. Of..., at 11:30 a.m. Tuesday. The lecture, which is underwritten by a grant from merck & Co., Inc., honors the late Robert Austrian, MD, a University of Penn...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

...tly and with its partners Bayer Schering, Nycomed, merck Serono and MedImmune." An archive of the even...t is developing adecatumumab in collaboration with merck Serono in a phase 1b clinical trial evaluating ade...ollaborators, including Bayer Schering, MedImmune, merck Serono, TRACON and Nycomed, for the funding or con...

Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin

...ver the finish line and into widespread use to prevent the devastating illnesses and deaths caused by malaria," said Adel Mahmoud, former president of merck Vaccines and member of Sanaria's board of directors. Ultimately, the measure of success will be a safe, effective licensed vaccine that is widely...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

...ing solid tumors. Micromet is developing adecatumumab in collaboration with merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination ...d the risks associated with reliance on collaborators, including MedImmune, merck Serono, TRACON and Nycomed, for the funding or conduct of further developme...

BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome

...t for the treatment of phenylketonuria (PKU), developed in partnership with merck Serono, a division of merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGyl...

Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line

...n pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's fingolimod (FTY-720) --- for the treatment of multiple sclerosis will be in the first line. Sur...

Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine

...ships with a number of global pharmaceutical companies, including Novartis, merck & Co., Inc., Wyeth, and Sanofi Pasteur. The Company's pipeline inc...I), a Phase II vaccine program for S. aureus, which is being developed with merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumoco...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

...ing solid tumors. Micromet is developing adecatumumab in collaboration with merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination ...d the risks associated with reliance on collaborators, including MedImmune, merck Serono, TRACON and Nycomed, for the funding or conduct of further developme...

Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results

...ein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

...ing solid tumors. Micromet is developing adecatumumab in collaboration with merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination ...d the risks associated with reliance on collaborators, including MedImmune, merck Serono, TRACON and Nycomed, for the funding or conduct of further developme...

Quark Pharmaceuticals Presents at Asia TIDES Conference

... was Director of Research and Development at Genta, and previously was Director of Biology Research at Ribozyme Pharmaceuticals, which was acquired by merck after changing its name to Sirna Therapeutics. About Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. is a development-stage pharm...

Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist

...f Project Management Angiogenesis. Kristian Jensen joins Pieris from merck Serono, where he spent almost three years establishing and managing its phage display antibody facility in Geneva, Switzerland. Prior to merck Serono, he obtained his research management experience during four years as...

Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial

...te Were met in Both Safinamide Dose Groups merck Serono, a division of merck KGaA, Darmstadt, Germany, and its partner Newron P... motor functioning," said Dr. Bernhard Kirschbaum, merck Serono's Executive Vice President for Global Resea...

Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers' Diarrhea Vaccine Study

... capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, merck & Co., Inc., Wyeth, Sanofi Pasteur, Kirin, and the Statens Serum Institut. Intercell is listed on the Prime Market of the Vienna Stock Exch...

Dr. Derek Winstanly of Quintiles to Serve as 2009 ACRO Chair; Mr. William Sharbaugh of PPD to Be Chair-Elect

...ined PPD in 2007 after spending more than 16 years in the pharmaceutical industry, including senior management positions with Bristol-Myers Squibb and merck & Co. As COO, he provides strategic direction and leadership to PPD's Phase II-IV clinical business, global central labs, information technology a...

Micromet Key Events for 2009

... MT201, a conventional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer....

NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis

..., NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic O...

Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals

...ein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including merck & Co., Inc. and Ortho-McNeil-Janssen Pharmaceuticals, Inc. Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the comp...

USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)

...capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, merck & Co., Inc., Wyeth, Sanofi Pasteur, Kyowa Hakko Kirin, and the Statens Serum Institut. The Company's leading product, a prophylactic vacci...

Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia

...ein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc. Forward-Looking Statements Certain statements in this press release are forward-...

Micromet Expands Committed Equity Financing Facility to $75 Million

... MT201, a conventional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer....

Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results

..., NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic O...

Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections

...ed study which is designed to evaluate the efficacy, safety, and tolerability of NXL104/ceftazidime vs. imipenem cilastatin (Primaxin(R) or Tienam(R), merck & Co. Inc., NYSE: MRK) in the treatment of adults with cUTIs. Complicated urinary tract infections include acute pyelonephritis, UTI in men, or UTI as...